Dupilumab
- Generic Name
- Dupilumab
- Brand Names
- Dupixent
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1190264-60-8
- Unique Ingredient Identifier
- 420K487FSG
- Background
Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reacti...
- Indication
In the US, dupilumab is indicated for the treatment of patients aged six months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. In Europe and Canada, the drug for this indication is approved for patients aged six years and older. In E...
- Associated Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Eosinophilic Esophagitis, Moderate to Severe Asthma, Moderate to Severe Atopic Dermatitis, Oral Steroid-Dependent Asthma (Disorder), Prurigo Nodularis, Severe Asthma, Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate Prurigo Nodularis, Severe Prurigo Nodularis
- Associated Therapies
- Add-on therapy, Maintenance therapy
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 48
- Registration Number
- NCT05983068
- Locations
- 🇺🇸
National Jewish Center Site Number : 8400001, Denver, Colorado, United States
🇺🇸St. Louis University SLUCare Academic Pavilion Site Number : 8400006, Saint Louis, Missouri, United States
🇺🇸New York University Langone Health Site Number : 8400004, New York, New York, United States
Mechanisms of Smell Improvement With Dupilumab.
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 50
- Registration Number
- NCT05964465
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid
- Conditions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT05906706
Dupilumab in Chinese Adult Participants With CRSwNP
- Conditions
- Interventions
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 63
- Registration Number
- NCT05878093
- Locations
- 🇨🇳
Investigational Site Number : 1560016, Jinan, China
🇨🇳Investigational Site Number : 1560001, Beijing, China
🇨🇳Investigational Site Number : 1560010, Chengdu, China
Dupilumab in the Treatment of Pediatric Alopecia Areata
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 76
- Registration Number
- NCT05866562
- Locations
- 🇺🇸
University of California, Irvine, Irvine, California, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Molecular Signatures of Cutaneous Dupilumab Response
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 15
- Registration Number
- NCT05858619
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Mind and Skin - the Neurocutaneous Axis in Atopic Eczema
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- King's College London
- Target Recruit Count
- 90
- Registration Number
- NCT05790330
- Locations
- 🇬🇧
Unit for Paediatric and Population-based Dermatology Research, London, United Kingdom
Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion
- Conditions
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2024-10-04
- Target Recruit Count
- 30
- Registration Number
- NCT05787678
- Locations
- 🇪🇸
Hospital de la Santa Creu i Sant Pau. Carrer Mas Casanovas 90., Barcelona, Spain
A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT05731128
- Locations
- 🇺🇸
Om Research- Site Number : 8400029, Apple Valley, California, United States
🇺🇸Advanced Research Institute - New Port Richey- Site Number : 8400026, New Port Richey, Florida, United States
🇺🇸TLC Clinical Research- Site Number : 8400020, Beverly Hills, California, United States
Dupilumab Effects Against Aeroallergen Challenge
- Conditions
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-04-08
- Target Recruit Count
- 88
- Registration Number
- NCT05720325
- Locations
- 🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
🇺🇸Biogenics Research Chamber, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.